• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    Improved process of compounds of formula III in which A denotes CH═CH or S W denotes O X denotes S, O or NR2 in which the residue R2 is hydrogen or C1-C6 alkyl, Y denotes CH or N R denotes naphthyl, thienyl or phenyl which is optionally monosubstituted or disubstituted with C1-C3 alkyl, CF3, C1-C3 alkoxy, F, Cl or bromine, R1 denotes hydrogen or C1-C6 alkyl and n denotes 1-3 by reducing a compound of the general formula IV, ,2 in which A, W, X, Y, R, R1 and n have the meanings stated above with activated aluminium in a protic solvent, as well as new compounds of formula III and pharmaceutical preparations containing these compounds.
    公开号:US20010008902A1
    申请号:US09/783,494
    申请日:2001-02-14
    公开日:2001-07-19
    发明作者:Hans-Frieder Kuhnle；Ernst-Christian Witte；Hans-Peter Wolff
    申请人:Hans-Frieder Kuhnle；Ernst-Christian Witte；Hans-Peter Wolff；
    IPC主号:C07D417-12
    专利说明:
    [0001] Thiazolidinedione derivatives of the general formula I are described in the application WO 94/27995, [0001]
    [0002] in which [0002]
    [0003] A represents a carbocyclic ring with 5 or 6 carbon atoms or a heterocyclic ring with a maximum of 4 heteroatoms in which the heteroatoms can be the same or different and denote oxygen, nitrogen or sulphur and the heterocycles can optionally carry an oxygen atom on one or several nitrogen atoms, [0003]
    [0004] B denotes —CH═CH—, —N═CH—, —CH═N—, O or S, [0004]
    [0005] W denotes CH[0005] 2, O, CH(OH), CO or —CH═CH—,
    [0006] X denotes S, O or NR[0006] 2, in which the residue R2 is hydrogen or C1-C6 alkyl,
    [0007] Y denotes CH or N [0007]
    [0008] R denotes naphthyl, pyridyl, furyl, thienyl or phenyl which is optionally monosubstituted or disubstituted with C[0008] 1-C3 alkyl, CF3, C1-C3 alkoxy, F, Cl or bromine,
    [0009] R[0009] 1 denotes hydrogen or C1-C6 alkyl and
    [0010] n denotes 1-3 [0010]
    [0011] as well as tautomers, enantiomers, diastereomers and physiologically tolerated salts thereof. [0011]
    [0012] Compounds of the general formula I can form salts with bases since they have an acidic NH group on the thiazolidinedione ring. Suitable pharmaceutical salts are for example alkali salts such as lithium, sodium or potassium salts, alkaline earth salts such as calcium or magnesium salts, other metal salts such as e.g. aluminium salts, ammonium salts or salts with organic bases such as e.g. diethanolamine, ethylenediamine, diisopropylamine and others. The sodium salt is particularly preferred. The salts are for example prepared by treating the compounds of the general formula (I) in a known manner with a stoichiometric amount of the corresponding base. [0012]
    [0013] The compounds are usually produced by a known process via alpha-halogenated carboxylic acids by subsequent synthesis of the thiazolidinedione ring system. In order to produce these carboxylic acids an aromatic amino group is diazotized and the diazonium salt is reacted with ethyl acrylate in the presence of hydrohalic acid and copper salts. This process has some disadvantages for the production of amounts on a multi-kg scale with regard to safety, upscaling, handling and synthesis complexity. For example in the reaction the aromatic amines must be diazotized to form the alpha-halogenated carboxylic acids and reacted with toxic acrylic acid ester and this reaction proceeds with unsatisfactory yields. Furthermore it is extremely problematic to apply this reaction to a larger scale for safety and environmental protection reasons. [0013]
    [0014] A further production process according to the invention comprises the catalytic hydrogenation of compounds of the general formula II, [0014]
    [0015] in which A, B, W, X, Y, R, R[0015] 1 and n have the meanings stated above.
    [0016] However, the catalytic hydrogenation is very complicated. A poisoning of the catalyst by sulphur may occur especially for types of compound which, in addition to the sulphur contained in the thiazolidinedione ring, carry a further sulphur atom in the molecule which leads to very long reaction periods and requires a several-fold renewal of the catalyst. [0016]
    [0017] A further process for the reduction of compounds of the general formula II is known from the literature which comprises the use of magnesium as a reducing agent [e.g. C. C. Cantello et al., in J. Med. Chem. 37, 3977 (1994)]. [0017]
    [0018] This method circumvents the interference of the catalytic process by sulphur contained in the molecule but in the case of the aforementioned compounds of the general formula II a partial reduction of the five-membered unsaturated heterocycle occurs which leads to impurities of the desired products that are difficult to separate. [0018]
    [0019] Surprisingly it has now been found that compounds of the general formula II can be smoothly reduced with a high purity by the method described last without a partial reduction of the double bonds of the five-membered heterocyclic ring system occurring if metallic aluminium is used instead of magnesium as a reducing agent, the aluminium being advantageously activated by treating the surface with salts of more noble metals. [0019]
    [0020] The process can be applied in particular to a selection of particularly valuable subclasses of the general formula I which are summarized in the following under the general formula III. [0020]
    [0021] Hence a subject matter of the invention is a new process for the production of compounds of the general formula (III) [0021]
    [0022] in which [0022]
    [0023] A denotes CH═CH or S [0023]
    [0024] W denotes O [0024]
    [0025] X denotes S, O or NR[0025] 2 in which the residue R2 is hydrogen or C1-C6 alkyl,
    [0026] Y denotes CH or N [0026]
    [0027] R denotes naphthyl, thienyl or phenyl which is optionally monosubstituted or disubstituted with C[0027] 1-C3 alkyl, CF3, C1-C3 alkoxy, F, Cl or bromine,
    [0028] R[0028] 1 denotes hydrogen or C1-C6 alkyl and
    [0029] n denotes 1-3 [0029]
    [0030] by reducing a compound of the general formula IV, [0030]
    [0031] in which A, W, X, Y, R, R[0031] 1 and n have the meanings stated above with activated aluminium in a protic solvent. The surface of the aluminium can be activated by treatment with metal salts that are above aluminium in the electrochemical series. A dilute solution of mercury chloride is particularly suitable. The aluminium can be used in the form of chippings, grit or powder. Lower alcohols, in particular methanol and also water are preferably used as the protic solvent. Aprotic organic solvents that are miscible with alcohols or water can be added to improve the solubility or can be used as the major component. The reaction is carried out at 0-80° C., preferably at room temperature or a slightly increased temperature up to 40° C.
    [0032] The invention also concerns new compounds of the general formula I which are not described in the application WO 94/27995 and which, in comparison to the compounds described in this application, exhibit a surprisingly better action profile in the treatment of diabetes mellitus. These are the following compounds: [0032]
    [0033] 5-{4-[2-(5-methyl-2-(thien-2-yl)-oxazol-4-yl)-ethoxy]-benzo[ b]thiophen-7-ylmethyl}-thiazolidine-2,4-dione [0033]
    [0034] 5-{4-[2-(5-methyl-2-(4-fluorophenyloxazol)-4-yl)-ethoxy]-benzo[ b]thiophen-7-ylmethyl}-thiazolidine-2,4-dione [0034]
    [0035] 5-{4-[2-(5-methyl-2-(4-chlorophenyloxazol)-4-yl)-ethoxy]-benzo[ b]thiophen-7-ylmethyl}-thiazolidine-2,4-dione [0035]
    [0036] 5-{4-[2-(5-methyl-2-(4-trifluoromethylphenyloxazol)-4-yl)-ethoxy]-benzo[ b]thiophen-7-ylmethyl}-thiazolidine-2,4-dione [0036]
    [0037] 5-{4-[2-(5-methyl-2-(2,4-difluorophenyloxazol)-4-yl)-ethoxy]-benzo[ b]thiophen-7-ylmethyl}-thiazolidine-2,4-dione [0037]
    [0038] tautomers, enantiomers, diastereomers and physiologically tolerated salts thereof. [0038]
    [0039] The invention in addition concerns pharmaceutical preparations which contain the compounds listed above as an active substance for the treatment of diabetes mellitus. The pharmaceutical preparations are produced and used according to conventional methods described in WO 94/27995. [0039]
    [0040] The following examples are intended to elucidate the new method for the production of compounds of formula (III) without limiting the method to the said special cases. The compounds of the general formula IV are produced according to the process stated in WO 94/27995. [0040] EXAMPLE 1 5-{4-[2-(5-Methyl-2-phenyloxazol-4-yl)-ethoxy]-benzo[ b]thiophen-7-ylmethyl}-thiazolidine-2,4-dione
    [0041] a) Production of Activated Aluminium [0041]
    [0042] 5 ml of a saturated solution of mercury II chloride in ethanol is diluted to 50 ml with ethanol and briefly shaken with 10 g aluminium needles. Then the solution is decanted and the needles are washed twice with ethanol, once with diethyl ether and once with tetrahydrofuran. [0042]
    [0043] b) Title Compound [0043]
    [0044] 10 g activated aluminium needles and 1 ml water are added to a solution of 2.03 g (4.3 mmol) 5-{4-[2-(5-Methyl-2-phenyloxazol-4-yl)-ethoxy]-benzo[b]thiophen-7-ylmethylidene}-thiazolidine-2,4-dione (Fp. 204-207° C.) in 130 ml tetrahydrofuran. Then it is heated for 50 min. while stirring to 50° C. and the solid components are removed by filtration. The filtrate is evaporated and the residue is chromatographed on silica gel with a mixture of 88 parts by volume toluene, 10 parts by volume 2-butanone and 2 parts by volume glacial acetic acid. Yield: 1.65 g (83%), Fp. 204-206° C. [0044] EXAMPLE 2
    [0045] The following are obtained in an analogous manner: [0045]
    [0046] a) 5-{4-[2-(5-Methyl-2-(thien-2-yl)-oxazol-4-yl)-ethoxy]-benzo[ b]thiophen-7-ylmethyl}-thiazolidine-2,4-dione [0046]
    [0047] Yield: 57%; Fp.: 115-117° C. from 5-{4-[2-(5-Methyl-2-(thien-2-yl)-oxazol-4-yl)-ethoxy]-benzo[ b]thiophen-7-ylmethylidene}-thiazolidine-2,4-dione (Fp. 229-234° C.). [0047]
    [0048] b) 5-{4-[2-(5-Methyl-2-phenyloxazol-4-yl)-ethoxy]-naphth-1-ylmethyl}-thiazolidine-2,4-dione [0048]
    [0049] Yield: 76%; Fp. 187-191° C. from 5-{4-[2-(5-Methyl-2-phenyl-oxazol-4-yl)-ethoxy]-naphth-1-ylmethylidene}-thiazolidine-2,4-dione (Fp.: 252-254° C.). [0049]
    [0050] c) 5-{4-[2-(5-Methyl-2-(4-fluorophenyloxazol)-4-yl)-ethoxy]-benzo[b]thiophen-7-ylmethyl}-thiazolidine-2,4-dione [0050]
    [0051] Yield: 81%, Fp. 205° C. from 5-{4-[2-(5-Methyl-2-(4-fluorophenyloxazol)-4-yl)-ethoxy]-benzo[ b]thiophen-7-yl-methylidene}-thiazolidine-2,4-dione (Fp. 240° C.). [0051]
    [0052] d) 5-{4-[2-(5-Methyl-2-(4-chlorophenyloxazol)-4-yl)-ethoxy]-benzo[b]thiophen-7-ylmethyl}-thiazolidine-2,4-dione [0052]
    [0053] Yield: 60%, Fp. 208° C. from 5-{4-[2-(5-Methyl-2-(4-chlorophenyloxazol)-4-yl)-ethoxy]-benzo[ b]thiophen-7-yl-methylidene}-thiazolidine-2,4-dione (Fp. 270° C.). [0053]
    [0054] e) 5-{4-[2-(5-Methyl-2-(4-trifluoromethylphenyloxazol)-4-yl)-ethoxy]-benzo[b]thiophen-7-ylmethyl}-thiazolidine-2,4-dione [0054]
    [0055] Yield: 57%; Fp. 191° C. from 5-{4-[2-(5-Methyl-2-(4-trifluoromethylphenyl)-oxazol-4-yl)-ethoxy]-benzo[b]thiophen-7-yl-methylidene}-thiazolidine-2,4 dione (Fp. 260° C.). [0055]
    [0056] f) 5-{4-[2-(5-Methyl-2-(2,4-difluorophenyloxazol)-4-yl)-ethoxy]-benzo[b]thiophen-7-ylmethyl}-thiazolidine-2,4-dione [0056]
    [0057] Yield: 78%; Fp. 189° C. from 5-{4-[2-(5-Methyl-2-(2,4-difluorophenyloxazol)-4-yl)-ethoxy]-benzo[b]thiophen-7-yl-methylidene}-thiazolidine-2,4-dione (amorphous, Fp. from 255° C.) [0057]
    权利要求:
    Claims (6)
    [1" id="US-20010008902-A1-CLM-00001] 1. Process for the production of compounds of the general formula III
    [2" id="US-20010008902-A1-CLM-00002] 2. Process as claimed in
    claim 1 , wherein the metallic aluminium used is activated by treatment of the surfaces with salts of noble metals.
    [3" id="US-20010008902-A1-CLM-00003] 3. Process as claimed in
    claim 1 or
    2 , wherein the aluminium is activated with a mercury chloride solution.
    [4" id="US-20010008902-A1-CLM-00004] 4. New compounds selected from the group
    5-{4-[2-(5-methyl-2-(thien-2-yl)-oxazol-4-yl)-ethoxy]-benzo[ b]thiophen-7-ylmethyl}-thiazolidine-2,4-dione
    5-{4-[2-(5-methyl-2-(4-fluorophenyloxazol)-4-yl)-ethoxy]-benzo[ b]thiophen-7-ylmethyl}-thiazolidine-2,4-dione
    5-{4-[2-(5-methyl-2-(4-chlorophenyloxazol)-4-yl)-ethoxy]-benzo[ b]thiophen-7-ylmethyl}-thiazolidine-2,4-dione
    5-{4-[2-(5-methyl-2-(4-trifluoromethylphenyloxazol)-4-yl)-ethoxy]-benzo[b]thiophen-7-ylmethyl}-thiazolidine-2,4-dione
    5-{4-[2-(5-methyl-2-(2,4-difluorophenyloxazol)-4-yl)-ethoxy]-benzo[ b]thiophen-7-ylmethyl}-thiazolidine-2,4-dione
    as well as tautomers, enantiomers, diastereomers and physiologically tolerated salts thereof
    [5" id="US-20010008902-A1-CLM-00005] 5. Pharmaceutical preparation containing a compound as claimed in
    claim 4 in addition to common carrier and auxiliary substances.
    [6" id="US-20010008902-A1-CLM-00006] 6. Use of compounds as claimed in
    claim 4 for the production of pharmaceutical preparations for the treatment of diabetes mellitus.
    类似技术:
    公开号 | 公开日 | 专利标题
    JP2004067697A|2004-03-04|New thiazolidinedione and application thereof
    JP2004067697A6|2004-08-05|Novel thiazolidinedione and its use
    Wipf et al.1995|Thiolysis of oxazolines: A new, selective method for the direct conversion of peptide oxazolines into thiazolines
    RU2129553C1|1999-04-27|Derivatives of thiazolidinedione, their synthesis and pharmaceutical composition
    US5585495A|1996-12-17|Reduction method for substituted 5-methylene-thiazolidinediones
    EP0008203A1|1980-02-20|Thiazolidine derivatives, preparing same and pharmaceutical compositions comprising same
    CA2111445C|1997-02-18|Process for the preparation of intermediates in the synthesis of chiral thiazolidine-2,4-dione derivatives
    EP2307369B1|2018-07-11|Marker reagents with a pyridine ring with a diazomethyl function substituent methods for synthesis of said reagents and methods for detecting biological molecules
    FR2965262A1|2012-03-30|NICOTINAMIDE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATION
    SK112099A3|2000-05-16|Process for the preparation of substituted thiazolidinedione
    EP2953935A2|2015-12-16|Method for producing pyrazoles, novel pyrazoles and applications thereof
    MXPA99008496A|2000-06-01|Improved method for producing thiazolidinediones, and new thiazolidinediones
    CZ333999A3|2000-01-12|Enhanced process for preparing thiazolidinediones and novel thiazolidinediones per se
    CN110642803B|2021-10-29|Synthesis method of dihydrothiazole heterocyclic compound and application of dihydrothiazole heterocyclic compound in modification of biological molecules
    JP2020505336A|2020-02-20|Method for producing chiral pyrrolidin-2-yl-methanol derivative
    WO2009104200A1|2009-08-27|A method for preparation of thiazolidinedione derivatives
    WO2006032218A1|2006-03-30|Method for the preparation of rosiglitazone
    KR20040050060A|2004-06-14|An intermediate of an optically active diarylalanine, its derivatives and process for prepararing the same
    同族专利:
    公开号 | 公开日
    AR012124A1|2000-09-27|
    RU2181724C2|2002-04-27|
    US6441185B2|2002-08-27|
    NO994505L|1999-11-17|
    CN1105718C|2003-04-16|
    EP0970077B1|2003-05-14|
    RS49771B|2008-06-05|
    IL131772A|2002-09-12|
    ES2198053T3|2004-01-16|
    TR199902197T2|1999-12-21|
    JP2000512312A|2000-09-19|
    KR20000076344A|2000-12-26|
    AU7036198A|1998-10-20|
    DE59808365D1|2003-06-18|
    CN1250448A|2000-04-12|
    ZA982326B|1999-09-20|
    NO313292B1|2002-09-09|
    KR100340353B1|2002-06-12|
    PL335903A1|2000-05-22|
    YU46699A|2002-06-19|
    TW487707B|2002-05-21|
    AU726048B2|2000-10-26|
    CA2285208C|2003-07-08|
    DE19711616A1|1998-09-24|
    HU0001551A3|2000-12-28|
    HK1025965A1|2000-12-01|
    CA2285208A1|1998-10-01|
    PL192201B1|2006-09-29|
    AT240324T|2003-05-15|
    WO1998042704A1|1998-10-01|
    DK0970077T3|2003-09-01|
    HU0001551A2|2000-11-28|
    US6258832B1|2001-07-10|
    PT970077E|2003-08-29|
    JP3484200B2|2004-01-06|
    EP0970077A1|2000-01-12|
    NO994505D0|1999-09-17|
    IL131772D0|2001-03-19|
    NZ337608A|2001-05-25|
    BR9808029A|2000-03-08|
    JP2004067697A|2004-03-04|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    CN1003445B|1984-10-03|1989-03-01|武田药品工业株式会社|The preparation method of thiazolidine diketone derivative|
    WO1986007056A1|1985-05-21|1986-12-04|Pfizer Inc.|Hypoglycemic thiazolidinediones|
    GB8713861D0|1987-06-13|1987-07-15|Beecham Group Plc|Compounds|
    EP0842925A1|1987-09-04|1998-05-20|Beecham Group Plc|Substituted thiazolidinedione derivatives|
    MX15171A|1988-03-08|1993-05-01|Pfizer|DERIVATIVES OF TIAZOLIDINODIONA HIPOGLICEMICOS|
    HU217432B|1988-03-08|2000-01-28|Pfizer Inc.|Process for producing thiazolidine-dion derivatives and pharmaceutical compositions containing the same the compounds and compositions|
    US5061717A|1988-03-08|1991-10-29|Pfizer Inc.|Thiazolidinedione hypoglycemic agents|
    US5330998A|1988-03-08|1994-07-19|Pfizer Inc.|Thiazolidinedione derivatives as hypoglycemic agents|
    EP0454501B1|1990-04-27|2001-09-05|Sankyo Company Limited|Benzylidenethiazolidine derivatives, their preparation and their use for the inhibition of lipid peroxides|
    DE69106714T2|1990-08-23|1995-05-11|Pfizer|HYPOGLYCAEMIC HYDROXY URINE DERIVATIVES.|
    JP2766730B2|1991-12-20|1998-06-18|ジ・アップジョン・カンパニー|Method for reducing substituted 5-methylene-thiazolidinedione|
    FR2688220B1|1992-03-06|1995-06-02|Adir||
    DE4317320A1|1993-05-25|1994-12-01|Boehringer Mannheim Gmbh|New thiazolidinediones and medicines containing them|
    ES2131301T3|1993-12-27|1999-07-16|Japan Tobacco Inc|DERIVED FROM ISOXAZOLIDINDIONA AND ITS USE.|EP1078923B1|1999-08-02|2006-03-08|F. Hoffmann-La Roche Ag|Process for the preparation of benzothiophene derivatives|
    US6531609B2|2000-04-14|2003-03-11|Hoffmann-La Roche Inc.|Process for the preparation of thiazolidinedione derivatives|
    FR2820742B1|2001-02-14|2005-03-11|Ppg Sipsy|PROCESS FOR THE PREPARATION OF COMPOUNDS DERIVED FROM THIAZOLIDINEDIONE, OXAZOLIDINEDIONE OR HYDANTOIN|
    FR2820741A1|2001-02-14|2002-08-16|Ppg Sipsy|Pure 5-alkyl-thiazolidinedione, oxazolidinedione or hydantoin derivative preparation, for use as drug or intermediate, by reduction of corresponding alkylidene compound using formic acid|
    EP1392296A1|2001-04-06|2004-03-03|F. Hoffmann-La Roche Ag|Thiazolidinediones alone or in conbination with other therapeutic agents for inhibiting or reducing tumour growth|
    NZ529033A|2001-05-15|2005-06-24|F|Carboxylic acid substituted oxazole derivatives for use as PPAR-alpha and -gamma activators in the treatment of diabetes|
    WO2004005266A1|2002-07-03|2004-01-15|F. Hoffmann-La Roche Ag|Oxazole derivatives and their use as insulin sensitizers|
    BR0313946A|2002-08-30|2005-07-12|Hoffmann La Roche|Compounds, process for the manufacture of these compounds, pharmaceutical compositions comprising them, methods for treating and / or preventing diseases that are modulated by pparaand / or ppary agonists, use of the compounds and / or method|
    AT345340T|2002-09-12|2006-12-15|Hoffmann La Roche|N-SUBSTITUTED-1H-INDOL-5-PROPANIC ACID COMPOUNDS AS PPAR AGONISTS FOR THE TREATMENT OF DIABETIS|
    BR0316556A|2002-11-25|2005-10-04|Hoffmann La Roche|Compounds, process for preparing a compound, pharmaceutical composition comprising such compound, its use and method for treating and / or prophylaxis of diseases that are modulated by pparand / or ppary agonists|
    MXPA05013732A|2003-06-26|2006-03-08|Hoffmann La Roche|Process for the preparation of insulin sensitizer and intermediate compound thereof.|
    法律状态:
    2006-02-01| FPAY| Fee payment|Year of fee payment: 4 |
    2010-04-05| REMI| Maintenance fee reminder mailed|
    2010-08-27| LAPS| Lapse for failure to pay maintenance fees|
    2010-09-27| STCH| Information on status: patent discontinuation|Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
    2010-10-19| FP| Expired due to failure to pay maintenance fee|Effective date: 20100827 |
    优先权:
    申请号 | 申请日 | 专利标题
    DE19711616||1997-03-20||
    DE19711616A|DE19711616A1|1997-03-20|1997-03-20|Improved process for the preparation of thiazolidinediones|
    WO98/01535||1998-03-17||
    PCT/EP1998/001535|WO1998042704A1|1997-03-20|1998-03-17|Improved method for producing thiazolidinediones, and new thiazolidinediones|
    US09/381,247|US6258832B1|1997-03-20|1998-03-17|Method for producing thiazolidinediones, and new thiazolidinediones|
    US09/783,494|US6441185B2|1997-03-20|2001-02-14|Method for producing thiazolidinediones, and new thiazolidinediones|US09/783,494| US6441185B2|1997-03-20|2001-02-14|Method for producing thiazolidinediones, and new thiazolidinediones|
    [返回顶部]